MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Fingolimod hydrochloride

CAS No. : 162359-56-0

MCE 站：Fingolimod hydrochloride

产品活性：Fingolimod hydrochloride (FTY720) 是鞘氨醇的类似物，是一种有效的 1-磷酸鞘氨醇 (S1P) 受体调节剂。Fingolimod hydrochloride 被鞘氨醇激酶磷酸化，特别是被 SK2 磷酸化，然后可与 S1PR1、3、4 和 5 结合。Fingolimod hydrochloride 诱导 S1P1 的内在化，因此抑制 S1P 的活性。Fingolimod hydrochloride 还是一种 pak1 激活剂。

研究领域：GPCR/G Protein  |  Cytoskeleton  |  Cell Cycle/DNA Damage

作用靶点：LPL Receptor  |  PAK

In Vitro: Fingolimod hydrochloride (FTY720) is a S1P antagonist with an IC₅₀ of 0.033 nM in K562 and NK cells.
The monocyte-derived immature dendritic cells (iDCs) are pretreated with various concentrations of S1P for various periods of time prior to their incubation with NK cells. Four hours incubation of autologous or allogeneic iDCs with 0.2-20 μM of S1P significantly protectes these cells from NK cell lysis. The IC₅₀ values of S1P are calculated at 160 nM for autologous iDCs, and 34 nM for allogeneic iDCs. Next, the inhibitory effect of S1P is revered by various concentrations of Fingolimod hydrochloride (FTY720) or SEW2871, with an IC₅₀ effect of 173 or 15 nM, respectively. The immunomodulator Fingolimod hydrochloride (FTY720) is a structural analogue of S1P and acts in its phosphorylated isoform as an unselective agonist on S1P₁ and S1P_3-5 and a selective functional antagonist on S1P₁.
FTY720 enhances serum S1P levels by inhibiting S1P lyase activity.
The number of Iba1⁺ cells in ipsilateral CA3 is counted, and the corresponding graph shows a significantly lower number of Iba1⁺ cells in CA3 of the Kainic acid (KA)+FTY720 group than in CA3 of KA group.

In Vivo: Administration of the immunomodulator Fingolimod hydrochloride (0.1 mg/kg i.v.) increases serum S1P, improves impaired systolic contractility and activates the PI3K-pathway in the heart. Administration of Fingolimod hydrochloride (FTY720) causes a significant rise in serum S1P levels in both sham-operated animals and animals challenged with LPS/PepG (P<0.0001). FTY720 attenuates microgliosis, modulates the microglia inflammatory phenotype by reducing LPS-mediated activation of p38 MAPK signalling pathway. Thus, FTY720 shares both direct neuroprotective and anti-inflammatory properties that can contribute to overall neuroprotection. In particular, the potential of FTY720 to switch microglia phenotype from a detrimental to a protective one represents a therapeutic mechanism for attenuating acute and chronic CNS damage.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Diabetes Related Compound Library  |  Anti-COVID-19 Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Neuroprotective Compound Library  |  PF-543 Citrate  |  IPA-3  |  5-Aminosalicylic Acid  |  Fingolimod  |  Ki16425  |  FRAX597  |  FRAX486  |  JTE-013  |  NVS-PAK1-1  |  G-5555  |  TY-52156  |  AM095  |  GNE 2861  |  Sphingosine-1-phosphate  |  FRAX1036  |  FTY720 (S)-Phosphate  |  LCH-7749944  |  SEW?2871  |  LPA2 antagonist 1  |  CYM-5541  |  ONO-7300243  |  1-Oleoyl lysophosphatidic acid  |  AS2717638  |  CYM50308  |  Radioprotectin-1  |  Ceranib-2  |  LPA2 antagonist 2  |  S1P1 Agonist III  |  CYM50260

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。